AlzeCure Pharma 首席执行官参加 Redeye 阿尔茨海默病活动。 CEO of AlzeCure Pharma participates in Redeye's Alzheimer's event.

瑞典中枢神经系统药物开发商 AlzeCure Pharma 宣布首席执行官 Martin Jönsson 将于 2024 年 3 月 21 日参加 Redeye 阿尔茨海默病活动。 AlzeCure Pharma, a Swedish CNS drug developer, announces CEO Martin Jönsson's participation in Redeye's Alzheimer's event on Mar 21, 2024. 此次活动将与 AlzeCure、Bioarctic 和 Alizinova 进行小组讨论，讨论其候选药物的科学、阿尔茨海默病治疗的剩余需求以及推出新一代药物。 The event will see a panel discussion with AlzeCure, Bioarctic, and Alizinova on their drug candidates' science, the remaining need for Alzheimer's treatments, and launching a new generation of drugs. AlzeCure 专注于治疗阿尔茨海默病和疼痛的小分子候选药物，有多种候选药物正在开发中。 AlzeCure specializes in small molecule drug candidates for Alzheimer's and pain, with several drug candidates in development.